NR and fatty liver: enzymes improved, liver fat did not

The primary finding should lead the story

A trial of nicotinamide riboside plus pterostilbene in adults with nonalcoholic fatty liver disease did not show a significant improvement in the primary liver-fat endpoint compared with placebo. Some secondary blood measurements improved in one active group. ^[1] Both findings belong in the answer. Describing the experiment only as a successful liver-inflammation study makes the evidence sound more decisive than its design permits.

The paper uses the historical term NAFLD, which identifies the population it studied. The important consumer distinction is between a change in liver enzymes and a demonstrated improvement in the amount of fat measured in the liver. Those observations can be scientifically related without being interchangeable proof of disease benefit.

What the six-month experiment actually compared

Dellinger and colleagues enrolled 111 adults and randomized them to placebo, 250 mg NR plus 50 mg pterostilbene daily, or double those amounts (500 mg plus 100 mg) in the combination sold as Basis. These describe the trial, not a personal regimen. The study lasted approximately six months. Magnetic-resonance measurement of hepatic fat fraction was the primary outcome. ^[1] This was a combination intervention, so the result cannot identify which component caused a particular change or establish that NR alone would do the same.

That limitation does not invalidate the trial. It defines the tested product concept. When a seller of another NAD product cites the paper, compare the actual ingredients before considering the headline. A plain NR capsule, an NMN powder and an NAD injection are different interventions even when they are grouped together under a cellular-health label.

The secondary signal is real but bounded

The lower combination amount produced favorable changes in ALT and GGT, and a change in ceramide 14:0 associated with ALT. The higher amount did not produce a clear dose-dependent version of those findings. ^[1] That makes a simple more-is-better interpretation inappropriate. It also means the favorable secondary results should not be used to rewrite the unsuccessful primary comparison.

A trial can generate useful secondary hypotheses while missing its main target. The appropriate next step is confirmation with a suitable design, rather than selecting the most appealing endpoint after the fact. For a consumer, the practical reading is straightforward: there is a signal worth investigating, but not evidence that choosing the largest bottle or highest amount produces the best liver result.

For the wider evidence context, read nad insulin sensitivity metabolic health.

Why enzymes and liver fat can tell different stories

A blood enzyme result and an imaging measure are different observations. A change in one does not logically force a change in the other, nor does it prove a reduction in future complications. The trial's own separation of primary and secondary outcomes helps prevent that confusion. ^[1]

Imagine a product summary that lists an enzyme reduction without mentioning the MRI result. The individual fact may be correct while the overall impression is misleading. A useful summary would say which measurement changed, which did not and which question was the prespecified main test. That approach does not demand that every study answer every clinical question. It simply prevents one laboratory improvement from being described as a comprehensive reversal of a condition.

Related NAD experiments cannot rescue a missed endpoint

The NMN study in postmenopausal women with prediabetes reported a muscle insulin-sensitivity result in a different population. ^[2] A separate short MIB-626 NMN experiment in overweight or obese adults reported several cardiometabolic changes but no improvement in hepatic fat or insulin sensitivity. ^[3] These papers help map the research landscape; they are not replications demonstrating that the NR–pterostilbene combination reduces liver fat.

The temptation is to blend every favorable NAD-related finding into one cumulative metabolic benefit. Resist it. Each study needs its own intervention and endpoint. A result in muscle cannot substitute for an unsuccessful liver imaging comparison, just as a cholesterol change cannot establish a clinical outcome that was never adequately tested.

Commercial confidence should match clinical uncertainty

Someone comparing Basis with plain NR should decide whether the additional pterostilbene is actually wanted. The existence of a combination trial is a reason to read the trial, not an automatic reason to prefer the blend. The relevant clinical question is whether the evidence matches the individual's diagnosis and intended result. The relevant commercial question is what formula and financial commitment are being purchased.

Keep those questions separate when considering a subscription. A six-month research duration is not a requirement to buy six months of product. Nor does a reported blood-marker change establish how long any individual should continue. Ask the treating clinician how liver-related findings are being evaluated and which changes would meaningfully affect care, rather than choosing a regimen from a retailer's most favorable study sentence.

A useful conclusion leaves the negative result visible

This trial supports continued investigation of NR–pterostilbene and selected inflammation-related markers, while failing to demonstrate the prespecified reduction in liver fat. ^[1] It does not establish a general NAD-product treatment for fatty liver, prove superiority of a higher amount or show that an injectable route would solve the unanswered question.

For a reader, the best use of the evidence is a more precise conversation. Name the diagnosis, the exact proposed product and the outcome being sought. Keep appropriate clinical follow-up in place. Product reviews can help compare ingredients, billing and convenience once that discussion is grounded. They cannot transform a secondary enzyme signal into a proven improvement in disease course. The research is informative precisely because the favorable and unfavorable results remain together.

For a practical assessment of the offering, see our Elysium Basis review; its purchase terms do not establish the clinical outcome.